FR2621817A1 - DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED - Google Patents

DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED Download PDF

Info

Publication number
FR2621817A1
FR2621817A1 FR8714345A FR8714345A FR2621817A1 FR 2621817 A1 FR2621817 A1 FR 2621817A1 FR 8714345 A FR8714345 A FR 8714345A FR 8714345 A FR8714345 A FR 8714345A FR 2621817 A1 FR2621817 A1 FR 2621817A1
Authority
FR
France
Prior art keywords
spraying
drug
nasal
polymyxin
tobramycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8714345A
Other languages
French (fr)
Other versions
FR2621817B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medipro
Original Assignee
Medipro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medipro filed Critical Medipro
Priority to FR8714345A priority Critical patent/FR2621817B1/en
Priority to EP19880909559 priority patent/EP0338062A1/en
Priority to PCT/FR1988/000513 priority patent/WO1989003673A1/en
Priority to AU26140/88A priority patent/AU2614088A/en
Publication of FR2621817A1 publication Critical patent/FR2621817A1/en
Application granted granted Critical
Publication of FR2621817B1 publication Critical patent/FR2621817B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

The invention concerns a drug for preventing gram-negative bacillary infections and mycoses in patients at risk, comprising the association of three antibiotics: polymyxin B, tobramycin and amphoterycin B, administered by precise spraying in the nasal and oropharyngeal cavities either in the form of a pressurized aerosol dispensed by a continuous or dosing valve or in the form of a mist spray dispensed by a precise pump. Two pushers are provided with each bottle: one having a long thin cannula for introduction into the nostrils and spraying of the nasal fossae, the other for generous spraying of the oropharyngeal cavity. The drug has a wide range of indications in all patients at risk of contracting a gram-negative bacillary infection or a mycosis.

Description

La présente invention concerne un médicament pour vaporisation destiné à prévenir les risques dtinfection chez les malades à risques en décontaminant les cavités nasales et oropharyngées
Les infections à bacilles gram négatif et les mycoses sont fréquentes chez les malades à risques . Elles entraînent une morbidité importante , elles sont une des causes principales du décès de ces patients , elles augmentent les dépenses de santé en augmentant les durées d'hospitalisation
La présente invention permet de remédier à cet inconvénient . Elle comporte l'associatign de trois antibiotiques administrée par vaporisation dans les cavités nasales et orophryngées . Les trois antibiotiques associés dans la préparation sont la polymyxine B , la tobramycine et l'amphotéricine B .La préparation doit adhérer aux muqueuses nasales et buccales , relarguer lentement les antibiotiques et avoir une tension superficielle permettant un talement maximal sur les muqueuses nasales et oropharyngées . La préparation est administrée par vaporisation précise soit sous forme d'aérosol pressurisé distribué par une valve continue ou doseuse soit sous forme de nébulisation distribuée par une pompe précise . Deux poussoirs sont fournis avec chaque flacon :: l'un disposant d'une canule longue et fine permettant l'introduction par les narines et la vaporisation des fosses nasales , l'autre d'une canule permettant une vaporisation large de la cavité oropharyngée
Les doses distribuées par les valves ou les pompes seront très précises
Elles sont bien entendu fonction de la concentration des antibiotiques au sein de la préparation
La fréquence des applications dépend également de la concentration de ces produits.
The present invention relates to a spray medication intended to prevent the risks of infection in patients at risk by decontaminating the nasal and oropharyngeal cavities.
Gram-negative bacillus infections and yeast infections are common in at-risk patients. They cause significant morbidity, they are one of the main causes of the death of these patients, they increase healthcare costs by increasing hospital stays
The present invention overcomes this drawback. It includes the combination of three antibiotics administered by spraying into the nasal and orophryngeal cavities. The three antibiotics associated in the preparation are polymyxin B, tobramycin and amphotericin B. The preparation must adhere to the nasal and oral mucous membranes, slowly release the antibiotics and have a surface tension allowing a maximum talement on the nasal and oropharyngeal mucous membranes. The preparation is administered by precise spraying either in the form of a pressurized aerosol dispensed by a continuous or metering valve or in the form of a nebulization dispensed by a precise pump. Two pushers are supplied with each bottle: one with a long and fine cannula allowing the introduction through the nostrils and vaporization of the nasal cavities, the other with a cannula allowing a broad vaporization of the oropharyngeal cavity
The doses distributed by the valves or the pumps will be very precise
They are of course a function of the concentration of antibiotics within the preparation
The frequency of applications also depends on the concentration of these products.

Aucun de ces antibiotiques n'étant absorbé par voie nasale , oropharyngée ou digestive , les posologies et donc les concentrations peuvent varier dans une très large part
Les caractéristiques et avantages de l'invention ressortent de la description qui va suivre à titre d'exemple : pour 30 ml de préparation , on associe
-sulfate de polymyxine B : 500 mg
-sulfate de tobramycine : 450 mg
-amphotéricine B : 2500 mg
-alcool à 900 : 1 ml
-saccharinate de sodium : 100 mg
-essence de menthe : 0,02ml
-glycérine : quantité suffisante
pour 30 ml
La valve ou la pompe doit être adaptée pour délivrer 0,5 ml à chaque pres sion . On recommande 6 pressions dans la cavité oropharyngée , 3 pressions dans chaque narine à chaque administration et une fréquence de quatre administrations par jour . Dans cet exemple , on administre 400 mg de polymyxine
B ,360 mg de tobramycine et 2000 mg d' amphotéricine B par jour
ilest recommandé d'associer la vaporisation nasale et oropharyngée à une décontamination sélective du tube digestif par administration orale ou par
s sonde gastrique avec ces même antibiotiques même antibiotiques
Les indications de ce médicament sont très larges : ildoit être employé chaque fois qu'un risque d'infection à gram négatif ou de mycose est présent: en réanimation , en hématologie , en chirurgie, en anesthésiologie , en cancérologie , etc...
None of these antibiotics being absorbed via the nasal, oropharyngeal or digestive route, the dosages and therefore the concentrations can vary to a very large extent.
The characteristics and advantages of the invention appear from the description which follows by way of example: for 30 ml of preparation, one associates
-polymyxin B sulfate: 500 mg
-tobramycin sulfate: 450 mg
-amphotericin B: 2500 mg
- 900 alcohol: 1 ml
-sodium saccharinate: 100 mg
-mint essence: 0.02ml
-glycerin: sufficient amount
for 30 ml
The valve or pump must be adapted to deliver 0.5 ml at each pressure. We recommend 6 pressures in the oropharyngeal cavity, 3 pressures in each nostril with each administration and a frequency of four administrations per day. In this example, 400 mg of polymyxin is administered
B, 360 mg tobramycin and 2000 mg amphotericin B per day
it is recommended to combine nasal and oropharyngeal spraying with selective decontamination of the digestive tract by oral administration or by
s gastric tube with these same antibiotics same antibiotics
The indications for this drug are very broad: it must be used whenever a risk of gram negative infection or mycosis is present: in intensive care, hematology, surgery, anesthesiology, oncology, etc ...

Claims (3)

REVENDICATIONS 1) Médicament destiné à prévenir les risques d'infections à bacilles gram négatif=caractérisé en ce qu'il comporte l'association de trois antîbiotit ques : polymyxine B ,tobramycine et amphotéricine B administrée par vaporisation dans les cavités nasales et oropharyngées 1) Medication intended to prevent the risks of infections with gram-negative bacilli = characterized in that it comprises the combination of three antibiotics: polymyxin B, tobramycin and amphotericin B administered by vaporization in the nasal and oropharyngeal cavities 2) Médicament selon la revendication 1 qaractérisé en ce que la préparation est administrée par vaporisation précise soit sous forme d'aérosol pressurisé- distribué par une valve continue ou doseuse soit sous forme de nebulisation distribuée par une pompe précise 2) Medicament according to claim 1 qaractérisé in that the preparation is administered by precise spraying either in the form of pressurized aerosol- dispensed by a continuous or metering valve or in the form of nebulization dispensed by a precise pump 3) Médicament selon l'une quelconque des revendications précédenteS caractérisé en ce que deux poussoirs sont fournis avec chaque flacon : : l'un disposant d'une canule longue et fine permettant l'introduction par les ouarines , l'autre d'une canule permettant une vaporisation large de la cavité oropharyngée  3) Medicament according to any one of the preceding claims, characterized in that two pushers are supplied with each bottle: one with a long and fine cannula allowing the introduction by the nostrils, the other with a cannula allowing wide vaporization of the oropharyngeal cavity
FR8714345A 1987-10-19 1987-10-19 DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED Expired - Lifetime FR2621817B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR8714345A FR2621817B1 (en) 1987-10-19 1987-10-19 DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED
EP19880909559 EP0338062A1 (en) 1987-10-19 1988-10-19 Drug comprising the association of polymyxin b, tobramycin and amphotericin b administered by spraying
PCT/FR1988/000513 WO1989003673A1 (en) 1987-10-19 1988-10-19 Drug comprising the association of polymyxin b, tobramycin and amphotericin b administered by spraying
AU26140/88A AU2614088A (en) 1987-10-19 1988-10-19 Drug comprising the association of polymyxin b, tobramycin and amphotericin b administered by spraying

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8714345A FR2621817B1 (en) 1987-10-19 1987-10-19 DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED

Publications (2)

Publication Number Publication Date
FR2621817A1 true FR2621817A1 (en) 1989-04-21
FR2621817B1 FR2621817B1 (en) 1990-12-14

Family

ID=9355910

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8714345A Expired - Lifetime FR2621817B1 (en) 1987-10-19 1987-10-19 DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED

Country Status (4)

Country Link
EP (1) EP0338062A1 (en)
AU (1) AU2614088A (en)
FR (1) FR2621817B1 (en)
WO (1) WO1989003673A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2290707A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of Amphotericin B
GB2290708A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of polyene macrolides
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
JP5670421B2 (en) 2009-03-31 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Component surface coating method
EP2432531B1 (en) 2009-05-18 2019-03-06 Boehringer Ingelheim International GmbH Adapter, inhalation device and nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5715640B2 (en) 2009-11-25 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nebulizer
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
EP2694220B1 (en) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medical device comprising a container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (en) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Atomiser with coding means
ES2836977T3 (en) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizer
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
CN106232166B (en) 2014-05-07 2020-04-14 勃林格殷格翰国际有限公司 Sprayer with a spray tube
PL3139984T3 (en) 2014-05-07 2021-11-08 Boehringer Ingelheim International Gmbh Nebulizer
CN106255554B (en) 2014-05-07 2021-05-04 勃林格殷格翰国际有限公司 Container, sprayer and use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL121455C (en) * 1900-01-01
GB1018125A (en) * 1962-11-29 1966-01-26 Merck & Co Inc Chemical products
AU539563B2 (en) * 1981-01-21 1984-10-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Primycin, doxycyline and sisomicin composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL121455C (en) * 1900-01-01
GB1018125A (en) * 1962-11-29 1966-01-26 Merck & Co Inc Chemical products
AU539563B2 (en) * 1981-01-21 1984-10-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Primycin, doxycyline and sisomicin composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"The Merck Index", édition 10, 1983, pages 85,1093,1358, Merck & Co., Rahway, NJ, US *

Also Published As

Publication number Publication date
WO1989003673A1 (en) 1989-05-05
FR2621817B1 (en) 1990-12-14
AU2614088A (en) 1989-05-23
EP0338062A1 (en) 1989-10-25

Similar Documents

Publication Publication Date Title
FR2621817A1 (en) DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED
FR2624015A1 (en) MEDICINE COMPRISING THE COMBINATION OF COLISTINE, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED
FR2621818A1 (en) MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION
ES2330415T3 (en) SYSTEM FOR OSMOTIC SUPPLY OF PHARMACEUTICAL ACTIVE AGENTS.
CA2039456A1 (en) Osmotic dosage system for liquid drug delivery
KR880013586A (en) Dosage device comprising a removable substrate with a solid state property
DK0998916T3 (en) Medicines for administration to the mucosa
KR880002502A (en) Formulations for Administration of Beneficial Acid Sensitive Agents
WO2000022909A3 (en) Systems for oral delivery
ES2104522T3 (en) NEW MEDICINAL ADMINISTRATION SYSTEM.
ATE138071T1 (en) LIPID AIDS FOR ADMINISTRATION THROUGH THE NOSE AND TOPICAL APPLICATION
US4876283A (en) Antisnoring agent
PT984762E (en) DEBIT CONTROLLER CONFIGURATIONS FOR AN ACTIVE AGENT ADMINISTRATION DEVICE
ES2171469T3 (en) COMPOSITION ADMINISTERED BY NASAL AND PREPARATION THAT CONTAINS IT.
CA1223210A (en) Antisnoring agent
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
KR970032872A (en) Drugs for the treatment of skin damage containing acetylsalicylic acid
FR2624017A1 (en) Medicament comprising a combination of colistin, amikacin and amphotericin B administered by vaporisation
FR2622113A1 (en) Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation
JP2002068963A (en) Liquid agent and container
FR2624738A1 (en) Medicament comprising a combination of colistin, sissomicin and amphotericin B administered by vaporisation
FR2624739A1 (en) Medicament comprising a combination of colistin, neomycin and amphotericin B administered by vaporisation
FR2622107A1 (en) Medicament comprising a combination of polymyxin B, sissomicin and amphotericin B administered by vaporisation
FR2622111A1 (en) Medicament comprising a combination of polymyxin B, dibekacin and amphotericin B administered by vaporisation
FR2624740A1 (en) Medicament comprising a combination of colistin, dibekacin and amphotericin B administered by vaporisation

Legal Events

Date Code Title Description
ST Notification of lapse